- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04116801
Evaluation of Resection Quality of Cerebral Metastases Using Fluorescence Guided Surgery: a Prospective Randomised Study (Fluomet)
October 3, 2019 updated by: Ramsay Générale de Santé
Evaluation of Resection Quality of Cerebral Metastases Using Fluorescence Guided Surgery: a Prospective Randomised Study- Fluomet Study
Few studies have evaluated the use of fluorescein sodium for the resection of brain tumours (especially glioblastomas) but also cerebral metastases.
We therefore propose to evaluate the technique of fluorescence guided microsurgery (fluorescein sodium) compared to the conventional microsurgical technique in the resection of cerebral metastases in adults in order to specify, by a prospective and randomised study, the assistance provided by this technique in the quality of resection and the gain in terms of overall survival and local control of brain disease.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Cerebral metastases are a major public health problem in cancer patients.
They are the most common brain tumours in adults.
It is estimated that approximately 20-40% of patients with primary malignant neoplasia will develop cerebral metastasis during the course of their illness.
In addition, the incidence of brain metastases is increasing due, in particular, to the aging of the population, as well as to the improvement of the overall management of cancer patients (cytotoxic or targeted systemic treatment) and easier access to magnetic resonance imaging (MRI), which improves patient survival.
The prognosis of patients with brain metastases is still poor and the median overall survival of these patients is of the order of a few months.
Although the management of brain metastases is multidisciplinary, the benefit of surgery has been clearly demonstrated in the literature.
Consequently, it is demonstrated that the quality of the tumour excision and in particular the carrying out of the complete excision of contrast enhancement on the MRI is correlated with improved overall survival (especially in case of single metastasis) and improved local control of the disease or progression-free survival, but also a better quality of life.
It is therefore essential to perform the most complete excision possible while minimising the associated morbidity.
For this purpose, various tools for surgical resection have been developed and are available, including intraoperative fluorescence guided surgery.
Sodium fluorescein is a fluorochrome that accumulates, after intravenous injection, into vascularised tumour tissues and is revealed intraoperatively by a light source of suitable wavelength (560 nm) using a set of lenses included in the microscope.
The resection is thus guided by this fluorescence, the complete disappearance of which will translate into a complete tumour resection.
Its interest is twofold: to increase the percentage of complete tumour resection and to improve survival without recurrence and overall survival.Few studies have evaluated the use of fluorescein sodium for the resection of brain tumours (especially glioblastomas) but also cerebral metastases.
If two studies on brain metastases showed a complete resection rate greater than 80% and a better rate of local control of brain disease, it is important to note that these studies were not randomised (with a control arm), they did not really prove the effectiveness of this technique under fluorescence, hence the need to set up a randomised study.
We therefore propose to evaluate the technique of fluorescence guided microsurgery (fluorescein sodium) compared to the conventional microsurgical technique in the resection of cerebral metastases in adults in order to specify, by a prospective and randomised study, the assistance provided by this technique in the quality of resection and the gain in terms of overall survival and local control of brain disease.
Study Type
Interventional
Enrollment (Anticipated)
94
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jean Francois OUDET
- Phone Number: +33683346567 +33683346567
- Email: jeanfrancois.oudet@free.fr
Study Locations
-
-
Paca
-
Marseille, Paca, France, 13009
- Recruiting
- Clairval Private Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female subject over the age of 18 and under the age of 85
- Subject presenting 1 to 5 cerebral secondary locations of which one lesion (contrast enhancement of at least 1 cm) is accessible to the most complete excision possible
- Unprotected adult within the meaning of the law
- Subject belonging to a health insurance scheme
- Absence of medical contraindications to surgery and anaesthesia
- Absence of medical contraindications to performing an MRI
- Known absence of allergy to the injectable form of Fluorescein sodium
- Subject having signed their written informed consent.
Exclusion Criteria:
- Subject who is a minor, pregnant, parturient or breastfeeding woman
- Adult subject under legal protection, guardianship or deprivation of liberty by judicial or administrative decision
- Subject hospitalised without consent
- Anatomical localisation (cerebral trunk, diencephalon) of the cerebral metastasis counter-indicating a wide excision at the discretion of the neurosurgeon
- Subject participating in a clinical trial or any other research involving human beings
- Subject taking beta-blockers
- Subject who has not signed a written informed consent.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Fluorescence arm
fluorescence guided microsurgical resection (under 560 nm filter) in addition to the usual techniques, after iv injection of 200 mg (i.e.
3-4 mg/kg) of fluorescein sodium at the time of skin incision.
|
resection of cerebral metastases by microsurgery
|
Active Comparator: Standard excision
microsurgical resection with usual techniques
|
resection of cerebral metastases by microsurgery
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quality excision
Time Frame: 48 hours
|
To evaluate the quality of excision in both neurosurgical techniques, in terms of complete resection of cerebral metastases, objectified by the absence of quantifiable tumour residues on early postoperative MRI (before 48 hours) in both groups, evaluated by one of the neuroradiologists associated with the project.
|
48 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 19, 2017
Primary Completion (Anticipated)
September 30, 2020
Study Completion (Anticipated)
September 30, 2020
Study Registration Dates
First Submitted
October 3, 2019
First Submitted That Met QC Criteria
October 3, 2019
First Posted (Actual)
October 7, 2019
Study Record Updates
Last Update Posted (Actual)
October 7, 2019
Last Update Submitted That Met QC Criteria
October 3, 2019
Last Verified
October 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2017-000515-16
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fluorescence Guided Surgery
-
University College, LondonUniversity College London HospitalsRecruitingFluorescence Guided SurgeryUnited Kingdom
-
Lee's Pharmaceutical LimitedNot yet recruiting5-aminolevulinic Acid | Fluorescence-guided ResectionChina
-
Amsterdam UMC, location VUmcEnrolling by invitation
-
Cairo UniversityUnknown
-
University Hospital, GrenobleCommissariat A L'energie Atomique; Institut National de la Santé et de la Recherche... and other collaboratorsUnknown
-
Kasr El Aini HospitalCairo UniversityCompletedUltrasound Guided | Hand SurgeryEgypt
-
Tanta UniversityNot yet recruitingAnalgesia | Ultrasound Guided Block | Pediatric Surgery
-
Tanta UniversityUnknownConventional Caudal Block | Ultrasound Guided Caudal Block | Ultrasound Guided Erector Spinae Block | Pediatric Hip SurgeryEgypt
-
Saint-Joseph UniversityEnrolling by invitationGuided Surgery | Immediate Implant Placement | Immediate TamporizationLebanon
-
Osstem AICCompletedComplications | Dental Implant Failed | Guided Surgery AccuracyItaly
Clinical Trials on microsurgical resection
-
University of UlmTerminated
-
Cantonal Hospital of St. GallenUniversity Hospital, Geneva; University Hospital Muenster; Stanford University; University of Toronto and other collaboratorsRecruitingSpinal Cord Neoplasms | Radiotherapy; Complications | Functional Outcome | Spinal Cord Metastasis | Spinal Cord Tumor Malignant IntramedullarySwitzerland
-
Medical University of ViennaRecruiting
-
Beijing Tiantan HospitalBeijing Friendship Hospital; Chinese PLA General Hospital; Xuanwu Hospital, Beijing and other collaboratorsUnknownIntracranial Arteriovenous MalformationsChina
-
Medical College of WisconsinRecruitingVestibular SchwannomaUnited States
-
Ministry of Science and Technology of the People´s...Beijing Municipal Science & Technology CommissionCompletedIntracranial Arteriovenous MalformationsChina
-
liuxingjuBeijing Municipal Science & Technology CommissionUnknownIntracranial AneurysmChina
-
Feng PanCompleted
-
University Hospital OstravaČeské Budějovice HospitalRecruitingAcute Stroke | Surgical ProcedureCzechia
-
Seoul National University HospitalCompletedVaricoceleKorea, Republic of